A phase 2a trial of the IL-33 mAb tozorakimab in patients with COPD: FRONTIER-4

A phase 2a trial of the IL-33 mAb tozorakimab in patients with COPD: FRONTIER-4

Interleukin-33 may have a role in COPD pathobiology. FRONTIER-4 (NCT04631016) investigated tozorakimab (an anti-IL-33 monoclonal antibody) in moderate-to-severe COPD patients with chronic bronchitis receiving dual or triple inhaled therapy. FRONTIER-4 was a phase 2a, randomized, double-blind, placeb...

Fuld beskrivelse

Saved in:
Bibliografiske detaljer
Main Authors: Dave Singh, Patricia Guller, Fred Reid, Sarah Doffman, Ulla Seppälä, Ioannis Psallidas, Rachel Moate, Rebecca Smith, Joanna Kiraga, Eulalia Jiménez, Dennis E. Brooks, Aoife Kelly, Lars H. Nordenmark, Muhammad Waqas Sadiq, Luis Mateos Caballero, Chris Kell, Maria G. Belvisi, Hitesh Pandya
Format: Artigo
Sprog:engelsk
Udgivet: 2025
Online adgang:https://doi.org/10.1183/13993003.02231-2024
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
Vær først til at give en kommentarø!
Du skal først være logget ind

Lignende værker